Efficacy, Safety of T2769 in Dry Eye Disease

Thea Pharma

Status: Completed

Conditions: Dry Eye Syndrome

Treatments: Other: T2769

Study type: Interventional

Funder types: Industry

Identifiers

NCT03830359

LT2769-001

Details and patient eligibility

About

Efficacy of T2769 in Dry Eye Desease

Full description

Multicenter and open study

Enrollment: 62 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed and dated informed consent
• Male or female aged from ≥ 18 years old
• Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study screening

Exclusion criteria

• Best far corrected visual acuity ≤ 2/10
• Severe blepharitis Severe dry eye

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

62 participants in 1 patient group

T2769

Experimental group

Description:

T2769 Ophthalmic solution patients treated with 1 drop in each eye 3 to 6 times daily

Treatment:

Other: T2769